Schering-Plough receives Indian approval for Viraferonpeg
This article was originally published in Scrip
Executive Summary
Schering-Plough's Indian affiliate,Fulford, has received local approval for Viraferonpeg vials, its pegylated interferon therapy, in combination with Rebetol (ribavirin) for chronic hepatitis C where prior treatment with alpha-interferon (pegylated or non-pegylated) and ribavirin combination therapy or alpha-interferon monotherapy have failed.